Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Hedrick

Showing results (101-110 of 103) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 103 results.
Journal of Proteomics|July 18, 2018
Embryonic atrazine exposure elicits proteomic, behavioral, and brain abnormalities with developmental time specific gene expression signaturesKatharine A Horzmann, Leeah S Reidenbach, Devang H Thanki, et al.
Blood|February 7, 2001
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic modelC H Moskowitz, S D Nimer, A D Zelenetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 1999
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphomaC H Moskowitz, J R Bertino, J R Glassman, et al.
Pageof 11

Showing results (101-110 of 103) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 103 results.
Journal of Proteomics|July 18, 2018
Embryonic atrazine exposure elicits proteomic, behavioral, and brain abnormalities with developmental time specific gene expression signaturesKatharine A Horzmann, Leeah S Reidenbach, Devang H Thanki, et al.
Blood|February 7, 2001
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic modelC H Moskowitz, S D Nimer, A D Zelenetz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 30, 1999
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphomaC H Moskowitz, J R Bertino, J R Glassman, et al.
Pageof 11